| Product Code: ETC8534853 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Overview |
3.1 Netherlands Country Macro Economic Indicators |
3.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, 2021 & 2031F |
3.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Industry Life Cycle |
3.4 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Porter's Five Forces |
3.5 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.8 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.9 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.10 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic obstructive pulmonary disease (COPD) in the Netherlands |
4.2.2 Rising geriatric population prone to COPD |
4.2.3 Technological advancements in COPD drug development |
4.2.4 Growing awareness about COPD and its treatment options |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval |
4.3.2 High cost associated with COPD drug development and treatment |
4.3.3 Competition from alternative treatment options like inhalers and nebulizers |
4.3.4 Limited accessibility to specialized healthcare facilities in rural areas |
5 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Trends |
6 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Types |
6.1 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Phosphodiestrase-4 Inhibitors, 2021- 2031F |
6.1.4 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Long-Acting Bronchodilators, 2021- 2031F |
6.1.5 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Short-Acting Bronchodilators, 2021- 2031F |
6.1.6 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Methylxanthines, 2021- 2031F |
6.1.7 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Product Type |
6.2.1 Overview and Analysis |
6.2.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Inhalers, 2021- 2031F |
6.2.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Nebulizers, 2021- 2031F |
6.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Type |
6.3.1 Overview and Analysis |
6.3.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Chronic Bronchitis, 2021- 2031F |
6.3.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Emphysema, 2021- 2031F |
6.4 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Diagnosis |
6.4.1 Overview and Analysis |
6.4.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Pirometry, 2021- 2031F |
6.4.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Diagnostic Tests, 2021- 2031F |
6.4.4 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Treatment |
6.5.1 Overview and Analysis |
6.5.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Oxygen Therapy, 2021- 2031F |
6.5.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Lung Transplant, 2021- 2031F |
6.5.4 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Drug Therapy, 2021- 2031F |
6.5.5 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Vaccination, 2021- 2031F |
6.5.6 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Surgery, 2021- 2031F |
6.5.7 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By End User |
6.6.1 Overview and Analysis |
6.6.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Hospitals & Clinics, 2021- 2031F |
6.6.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Home Care Settings, 2021- 2031F |
6.6.4 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
7 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Import-Export Trade Statistics |
7.1 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Export to Major Countries |
7.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Imports from Major Countries |
8 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Key Performance Indicators |
8.1 Patient adherence rate to prescribed COPD medications |
8.2 Number of COPD-related hospital admissions |
8.3 Average age of COPD patients diagnosed in the Netherlands |
8.4 Rate of adoption of new COPD treatment guidelines |
8.5 Number of COPD clinical trials conducted in the Netherlands |
9 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Opportunity Assessment |
9.1 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.3 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Type, 2021 & 2031F |
9.4 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.5 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.6 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Competitive Landscape |
10.1 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenue Share, By Companies, 2024 |
10.2 Netherlands Chronic Obstructive Pulmonary Disease (COPD) Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here